| Literature DB >> 27244447 |
Byung-Whi Kong1, Kentu Lassiter1, Alissa Piekarski-Welsher1, Sami Dridi1, Antonio Reverter-Gomez2, Nicholas James Hudson2, Walter Gay Bottje1.
Abstract
As feed represents 60 to 70% of the cost of raising an animal to market weight, feed efficiency (the amount of dry weight intake to amount of wet weight gain) remains an important genetic trait in animal agriculture. To gain greater understanding of cellular mechanisms of feed efficiency (FE), shotgun proteomics was conducted using in-gel trypsin digestion and tandem mass spectrometry on breast muscle samples obtained from pedigree male (PedM) broilers exhibiting high feed efficiency (FE) or low FE phenotypes (n = 4 per group). The high FE group had greater body weight gain (P = 0.004) but consumed the same amount of feed (P = 0.30) from 6 to 7 wk resulting in higher FE (P < 0.001). Over 1800 proteins were identified, of which 152 were different (P < 0.05) by at least 1.3 fold and ≤ 15 fold between the high and low FE phenotypes. Data were analyzed for a modified differential expression (DE) metric (Phenotypic Impact Factors or PIF) and interpretation of protein expression data facilitated using the Ingenuity Pathway Analysis (IPA) program. In the entire data set, 228 mitochondrial proteins were identified whose collective expression indicates a higher mitochondrial expression in the high FE phenotype (binomial probability P < 0.00001). Within the top up and down 5% PIF molecules in the dataset, there were 15 mitoproteome proteins up-regulated and only 5 down-regulated in the high FE phenotype. Pathway enrichment analysis also identified mitochondrial dysfunction and oxidative phosphorylation as the number 1 and 5 differentially expressed canonical pathways (up-regulated in high FE) in the proteomic dataset. Upstream analysis (based on DE of downstream molecules) predicted that insulin receptor, insulin like growth receptor 1, nuclear factor, erythroid 2-like 2, AMP activated protein kinase (α subunit), progesterone and triiodothyronine would be activated in the high FE phenotype whereas rapamycin independent companion of target of rapamycin, mitogen activated protein kinase 4, and serum response factor would be inhibited in the high FE phenotype. The results provide additional insight into the fundamental molecular landscape of feed efficiency in breast muscle of broilers as well as further support for a role of mitochondria in the phenotypic expression of FE. Funding provided by USDA-NIFA (#2013-01953), Arkansas Biosciences Institute (Little Rock, AR), McMaster Fellowship (AUS to WB) and the Agricultural Experiment Station (Univ. of Arkansas, Fayetteville).Entities:
Mesh:
Substances:
Year: 2016 PMID: 27244447 PMCID: PMC4887024 DOI: 10.1371/journal.pone.0155679
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1SDS-PAGE gel electrophoresis in broiler breast muscle.
Protein bands prior to protein extractions of breast muscle obtained from pedigree broiler breeder males exhibiting low feed efficiency (L) or high feed efficiency (H) (n = 4 per group). From this gel, a total of 25 slices were obtained and subjected to tryptic digestion prior to conducting shotgun proteomics.
Protein expression (Fold Change) in breast muscle obtained from a single male broiler breeder line individually phenotyped for high or low FE (n = 4 per group).
Positive and negative fold change values indicates proteins that were up-regulated in high FE and low FE broiler males, respectively, with significance level designated by P-values.
| Symbol | Entrez Gene Name | Fold Change | P value |
|---|---|---|---|
| KRT15 | keratin 15 | 13.70 | 0.036 |
| CACNA1S | calcium channel, voltage-dependent, L type, alpha 1S subunit | 12.08 | 0.004 |
| IDE | insulin-degrading enzyme | 11.69 | 0.004 |
| SLC25A4 | solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 | 10.32 | 0.002 |
| PHKG1 | phosphorylase kinase, gamma 1 (muscle) | 9.81 | 0.005 |
| CAV1 | caveolin 1, caveolae protein, 22kDa | 9.40 | 0.009 |
| FABP4 | fatty acid binding protein 4, adipocyte | 9.31 | 0.012 |
| CKB | creatine kinase, brain | 8.91 | 0.003 |
| PPA2 | pyrophosphatase (inorganic) 2 | 8.85 | 0.007 |
| ARF4 | ADP-ribosylation factor 4 | 8.81 | 0.004 |
| NDUFV2 | NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa | 8.77 | 0.003 |
| PTRH2 | peptidyl-tRNA hydrolase 2 | 7.78 | 0.001 |
| EIF4G2 | eukaryotic translation initiation factor 4 gamma, 2 | 7.68 | 0.015 |
| SNAP23 | synaptosomal-associated protein, 23kDa | 7.55 | 0.008 |
| APRT | adenine phosphoribosyltransferase | 7.28 | 0.038 |
| SAR1B | secretion associated, Ras related GTPase 1B | 6.99 | 0.019 |
| OTUB1 | OTU deubiquitinase, ubiquitin aldehyde binding 1 | 6.66 | 0.051 |
| G3BP1 | GTPase activating protein (SH3 domain) binding protein 1 | 6.59 | 0.002 |
| MYO18A | myosin XVIIIA | 6.50 | 0.017 |
| MTHFD1L | methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like | 6.24 | 0.047 |
| RAP1B | RAP1B, member of RAS oncogene family | 6.02 | 0.001 |
| IPO7 | importin 7 | 5.94 | 0.006 |
| ARF1 | ADP-ribosylation factor 1 | 5.75 | 0.010 |
| GLRX3 | glutaredoxin 3 | 5.66 | 0.004 |
| NDUFB8 | NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa | 5.64 | 0.005 |
| PHKB | phosphorylase kinase, beta | 5.49 | 0.033 |
| SNX3 | sorting nexin 3 | 5.38 | 0.034 |
| DHRS7C | dehydrogenase/reductase (SDR family) member 7C | 5.13 | 0.058 |
| NDUFS7 | NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-coenzyme Q Red.) | 4.79 | 0.049 |
| SKP1 | S-phase kinase-associated protein 1 | 4.78 | 0.054 |
| PRPS1 | phosphoribosyl pyrophosphate synthetase 1 | 4.60 | 0.027 |
| TARS | threonyl-tRNA synthetase | 4.52 | 0.017 |
| UBE2H | ubiquitin-conjugating enzyme E2H | 4.29 | 0.028 |
| PTRF | polymerase I and transcript release factor | 4.25 | 0.006 |
| UQCRC1 | ubiquinol-cytochrome c reductase core protein I | 4.11 | 0.059 |
| NME3 | NME/NM23 nucleoside diphosphate kinase 3 | 4.06 | 0.019 |
| GNB2L1 | guanine nucleotide binding protein (G protein), beta polypeptide 2-like 1 | 3.99 | 0.001 |
| RPL30 | ribosomal protein L30 | 3.91 | 0.043 |
| USP9X | ubiquitin specific peptidase 9, X-linked | 3.89 | 0.023 |
| RAB7A | RAB7A, member RAS oncogene family | 3.78 | 0.021 |
| RYR3 | ryanodine receptor 3 | 3.73 | 0.006 |
| SPTB | spectrin, beta, erythrocytic | 3.69 | 0.001 |
| NARS | asparaginyl-tRNA synthetase | 3.60 | 0.014 |
| TPP2 | tripeptidyl peptidase II | 3.58 | 0.048 |
| RAB5B | RAB5B, member RAS oncogene family | 3.52 | 0.033 |
| NUB1 | negative regulator of ubiquitin-like proteins 1 | 3.33 | 0.047 |
| RAB8B | RAB8B, member RAS oncogene family | 3.31 | 0.027 |
| ARL6IP5 | ADP-ribosylation factor-like 6 interacting protein 5 | 3.31 | 0.005 |
| ATP5O | ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit | 3.26 | 0.001 |
| COPS7A | COP9 signalosome subunit 7A | 3.12 | 0.008 |
| GPX1 | glutathione peroxidase 1 | 3.09 | 0.004 |
| CANX | Calnexin | 3.04 | 0.010 |
| VBP1 | von Hippel-Lindau binding protein 1 | 3.02 | 0.024 |
| Cyb5r3 | cytochrome b5 reductase 3 | 3.00 | 0.012 |
| DMD | Dystrophin | 2.87 | 0.000 |
| PRDX3 | peroxiredoxin 3 | 2.85 | 0.008 |
| LYPLA1 | lysophospholipase I | 2.84 | 0.008 |
| VDAC2 | voltage-dependent anion channel 2 | 2.83 | 0.031 |
| PSMD1 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 1 | 2.83 | 0.013 |
| Rrbp1 | ribosome binding protein 1 | 2.76 | 0.050 |
| CTH | cystathionine gamma-lyase | 2.72 | 0.023 |
| PSMD2 | proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 | 2.70 | 0.035 |
| GLO1 | glyoxalase I | 2.68 | 0.011 |
| FSD2 | fibronectin type III and SPRY domain containing 2 | 2.68 | 0.019 |
| UBE2N | ubiquitin-conjugating enzyme E2N | 2.66 | 0.010 |
| COX4I1 | cytochrome c oxidase subunit IV isoform 1 | 2.63 | 0.019 |
| CUL3 | cullin 3 | 2.61 | 0.015 |
| GLUD1 | glutamate dehydrogenase 1 | 2.60 | 0.001 |
| DCUN1D2 | DCN1, defective in cullin neddylation 1, domain containing 2 | 2.60 | 0.050 |
| LANCL2 | LanC lantibiotic synthetase component C-like 2 (bacterial) | 2.58 | 0.059 |
| Ktn1 | kinectin 1 | 2.57 | 0.027 |
| SGCG | sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) | 2.51 | 0.048 |
| CARS | cysteinyl-tRNA synthetase | 2.49 | 0.018 |
| RAB12 | RAB12, member RAS oncogene family | 2.44 | 0.049 |
| UQCRC2 | ubiquinol-cytochrome c reductase core protein II | 2.41 | 0.003 |
| VDAC1 | voltage-dependent anion channel 1 | 2.40 | 0.004 |
| EIF3B | eukaryotic translation initiation factor 3, subunit B | 2.37 | 0.042 |
| CISD2 | CDGSH iron sulfur domain 2 | 2.30 | 0.009 |
| OARD1 | O-acyl-ADP-ribose deacylase 1 | 2.29 | 0.029 |
| KLHL40 | kelch-like family member 40 | 2.28 | 0.046 |
| OGDH | oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) | 2.26 | 0.028 |
| PPIB | peptidylprolyl isomerase B (cyclophilin B) | 2.24 | 0.020 |
| CSPG4 | chondroitin sulfate proteoglycan 4 | 2.13 | 0.045 |
| YWHAG | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma | 2.10 | 0.016 |
| YWHAH | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta | 2.07 | 0.015 |
| TMED10 | transmembrane emp24-like trafficking protein 10 (yeast) | 2.06 | 0.007 |
| ALDH1L2 | aldehyde dehydrogenase 1 family, member L2 | 2.05 | 0.018 |
| PSMB1 | proteasome (prosome, macropain) subunit, beta type, 1 | 2.02 | 0.044 |
| EMC2 | ER membrane protein complex subunit 2 | 1.98 | 0.030 |
| RPL12 | ribosomal protein L12 | 1.98 | 0.009 |
| HSPB2 | heat shock 27kDa protein 2 | 1.96 | 0.028 |
| DHRS7B | dehydrogenase/reductase (SDR family) member 7B | 1.96 | 0.037 |
| ATP2B4 | ATPase, Ca++ transporting, plasma membrane 4 | 1.93 | 0.013 |
| SPTAN1 | spectrin, alpha, non-erythrocytic 1 | 1.86 | 0.031 |
| PFKM | phosphofructokinase, muscle | 1.86 | 0.001 |
| MYOM2 | myomesin 2 | 1.84 | 0.007 |
| MYLK2 | myosin light chain kinase 2 | 1.83 | 0.039 |
| DDX1 | DEAD (Asp-Glu-Ala-Asp) box helicase 1 | 1.80 | 0.018 |
| PSMA5 | proteasome (prosome, macropain) subunit, alpha type, 5 | 1.79 | 0.019 |
| BAG3 | BCL2-associated athanogene 3 | 1.76 | 0.034 |
| SRL | Sarcalumenin | 1.71 | 0.006 |
| AMPD1 | adenosine monophosphate deaminase 1 | 1.68 | 0.046 |
| NDUFS8 | NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q) | 1.61 | 0.014 |
| CACNA2D1 | calcium channel, voltage-dependent, alpha 2/delta subunit 1 | 1.57 | 0.053 |
| ANXA4 | annexin A4 | 1.54 | 0.025 |
| DCTN2 | dynactin 2 (p50) | -11.19 | 0.006 |
| UBQLN4 | ubiquilin 4 | -7.95 | 0.012 |
| SPINK5 | serine peptidase inhibitor, Kazal type 5 | -7.61 | 0.015 |
| BCAP29 | B-cell receptor-associated protein 29 | -7.24 | 0.018 |
| CAPZA2 | capping protein (actin filament) muscle Z-line, alpha 2 | -5.93 | 0.038 |
| C4BPA | complement component 4 binding protein, alpha | -5.62 | 0.012 |
| EIF4G1 | eukaryotic translation initiation factor 4 gamma, 1 | -5.06 | 0.014 |
| EDF1 | endothelial differentiation-related factor 1 | -3.88 | 0.033 |
| ALDH9A1 | aldehyde dehydrogenase 9 family, member A1 | -3.85 | 0.029 |
| USP15 | ubiquitin specific peptidase 15 | -3.77 | 0.026 |
| SMYD1 | SET and MYND domain containing 1 | -3.74 | 0.028 |
| EML1 | echinoderm microtubule associated protein like 1 | -3.24 | 0.015 |
| PABPC1 | poly(A) binding protein, cytoplasmic 1 | -3.23 | 0.008 |
| NAP1L1 | nucleosome assembly protein 1-like 1 | -3.20 | 0.018 |
| ACTA1 | actin, alpha 1, skeletal muscle | -2.89 | 0.000 |
| UBE2V1 | ubiquitin-conjugating enzyme E2 variant 1 | -2.85 | 0.019 |
| SOD1 | superoxide dismutase 1, soluble | -2.81 | 0.015 |
| PABPC4 | poly(A) binding protein, cytoplasmic 4 (inducible form) | -2.76 | 0.009 |
| ACTC1 | actin, alpha, cardiac muscle 1 | -2.71 | 0.000 |
| MYBPC2 | myosin binding protein C, fast type | -2.59 | 0.000 |
| ALB | Albumin | -2.57 | 0.004 |
| FKBP4 | FK506 binding protein 4, 59kDa | -2.51 | 0.058 |
| IQGAP1 | IQ motif containing GTPase activating protein 1 | -2.46 | 0.163 |
| ACTG1 | actin, gamma 1 | -2.32 | 0.012 |
| MYL1 | myosin, light chain 1, alkali; skeletal, fast | -2.09 | 0.001 |
| PEPD | peptidase D | -2.09 | 0.004 |
| SARS | seryl-tRNA synthetase | -2.08 | 0.031 |
| CAMK2D | calcium/calmodulin-dependent protein kinase II delta | -2.05 | 0.015 |
| APOA1 | apolipoprotein A-I | -2.00 | 0.057 |
| PACSIN3 | protein kinase C and casein kinase substrate in neurons 3 | -1.81 | 0.011 |
| FBP2 | fructose-1,6-bisphosphatase 2 | -1.77 | 0.008 |
| NAP1L4 | nucleosome assembly protein 1-like 4 | -1.75 | 0.024 |
| CCT2 | cell division cycle 42 | -1.67 | 0.010 |
| RAB11A | RAB11A, member RAS oncogene family | -1.67 | 0.032 |
| CCT2 | chaperonin containing TCP1, subunit 2 (beta) | -1.64 | 0.002 |
| GPI | glucose-6-phosphate isomerase | -1.59 | 0.043 |
| ENO2 | enolase 2 (gamma, neuronal) | -1.58 | 0.044 |
| EEF1A1 | eukaryotic translation elongation factor 1 alpha 1 | -1.52 | 0.029 |
| PBLD | phenazine biosynthesis-like protein domain containing | -1.49 | 0.044 |
| LDB3 | LIM domain binding 3 | -1.49 | 0.019 |
| EIF4A2 | eukaryotic translation initiation factor 4A2 | -1.49 | 0.015 |
| HN1L | hematological and neurological expressed 1-like | -1.46 | 0.040 |
| GAPDH | glyceraldehyde-3-phosphate dehydrogenase | -1.45 | 0.055 |
| EEF1A2 | eukaryotic translation elongation factor 1 alpha 2 | -1.44 | 0.015 |
| P4HB | prolyl 4-hydroxylase, beta polypeptide | -1.44 | 0.052 |
| CKM | creatine kinase, muscle | -1.41 | 0.036 |
| CAP2 | CAP, adenylate cyclase-associated protein, 2 (yeast) | -1.31 | 0.014 |
Fig 2The protein abundance for the difference (Minus [M] for high FE minus low FE) and protein abundance alone (A) for all proteins.
The MA plot is consistent with a reduction in slow fiber subunits (TPM2, ACTC) in the high FE (HFE) and an increase in mitochondrial regulators of muscle energy supply in the form of ATP (SLC25A4) and creatine phosphate (VDAC2). GAPDH is the most abundant protein we identified. Further, the mitoproteome (highlighted in red, Fig 2A) is skewed towards the HFE consistent with a higher mitochondrial content. Highly differentially expressed proteins were identified by a metric called Phenotypic Impact Factor (PIF), with the extreme 10% highlighted in blue (Fig 2B). Abbreviations: (RTN4), reticulon 4; (PHKG1), phosphorylase kinase gamma 1; (SLC26A4), adenine nucleotide translocase 1; (ACTC), alpha actin cardiac; (Gga), golgi associated gamma adaptin; (GAPDH) glyceraldyhde 3-phosphate dehydrogenase; (TPM2), tropomyosin 2.
Fig 3A hierarchically clustered heat map of the 40 most differentially expressed proteins as identified by PIF.
Each cell contains the normalized expression of the protein at the individual bird level. Red denotes high expression, green denotes low expression. All 8 birds discriminate into their correct treatment group of origin (HFE or LFE) and relatedness within a group is also apparent. Proteins are clustered by patterns of co-expression across the 8 birds. Strong co-expression is observed for functionally related proteins e.g. ARF1 with ARF4 and KRT3 with KRT5 and KRT14 and the muscle structural proteins, namely TPM1, TPM2 and CAPZB. Different fragment of the same protein are highly co-expressed. Note: ‘B’ are birds with a low FE phenotype whereas ‘G’ are birds with a high FE phenotype. Abbreviations: (RTN4), reticulon 4; (NDUFV2), NADH dehydrogenase (ubiquinone) Fe-S protein 7; (PHKG1), phosphorylase kinase gamma 1; (IDE), insulin degrading enzyme; (CACNA15), calcium channel voltage dependent 1 L type, alpha 15; (ARF), ADP ribosylation factor 4 and 1; (SAR1B), SAR1-ADP ribosylation factor, (SPEG), striated muscle preferentially expressed protein; (Gga), golgi associated gamma adaptin; (RYR3) ryanodine receptor 3; (SLC26A4), adenine nucleotide translocase 1; (MYO18A), myosin 18A; (KRT), keratin; (TPM), tropomyosin; (BAT2), large proline rich protein; (CAPZB), F-actin capping protein subunit beta; (DCTN2), dynactin 2; (ACTA1), alpha actin 1; (GSN), gelsolin; (SMYD1), myosin interacting protein; (NEB), lambda protein phosphatase; (OIH) ovoinhibitor; (UBQLN), ubituilin family proteins
Abbreviations and names of proteins not found in Table 1 or figure legends.
| Abbreviation | Protein Name |
|---|---|
| C1QBP | Complement component 1Q subcomponent binding protein |
| COQ9 | Coenzyme Q9 (mitochondrial) |
| DES | Desmin |
| DSP | Desmoplakin |
| JUP | Junction plakoglobin |
| LDHA | Lactate Dehydrogenase A |
| LMB2 | Lamin B2 |
| MYOM2 | Myomesin 2 |
| MYH2 | Myosin Heayy Chain 2 |
| PKM | Pyruvate kinase (muscle) |
| PPA2 | Pyrophosphatase (inorganic)2 |
| PTRH2 | Peptidyl tRNA hydrolase (mitochondrial) |
| SYMN | Synem |
Top canonical pathways.
The top 6 canonical pathways (based on p value) generated by Ingenuity Pathway Analysis based on differentially expressed proteins in breast muscle obtained from broiler breeder males.
| Canonical Pathway | p Value |
|---|---|
| Mitochondrial Dysfunction | 4.85E-09 |
| Glycolysis I | 9.24E-07 |
| Caveolar-mediated Endocytosis Signaling | 9.62E-07 |
| Clathrin-mediated Endocytosis Signaling | 1.10E-06 |
| Oxidative Phosphorylation | 1.38E-06 |
| Protein Ubiquitination | 2.87E-06 |
Fig 4The canonical pathway of oxidative phosphorylation.
The canonical pathway of oxidative phosphorylation (generated by the IPA program) showing; A) The differential expression of proteins in breast muscle associated with the electron transport chain on (Complex I, II, III, IV, and V) that were up-regulated (outlined in pink) in the high feed efficiency phenotype. Pumping of hydrogen ions (H+) creates a proton motive force between the inner (IMM) and outer (OMM) mitochondrial membranes that is used to drive ATP synthesis B) Using the molecule activity predictor function of IPA for the oxidative phosphorylation pathway, the results indicate that Complex I, III, and IV, and V in breast muscle are predicted to have greater activity (indicated by the orange color) in the high compared to the low FE phenotype.
Upstream regulators predicted to be activated or inhibited in the proteomic dataset.
| Upstream Regulator | Predicted Activity (In HFE) | Activation z-score | p-value of overlap | |
|---|---|---|---|---|
| INSR | Activated | 2.425 | 4.29E-05 | ACTA1, GAPDH, |
| NFE2L2 | Activated | 2.382 | 1.54E-06 | ACTG1, SOD1, |
| IGF1R | Activated | 2.236 | 2.95E-04 | ACTA1, |
| progesterone | +++ | 1.954 | 4.55E-02 | ACTA1, |
| PRKAA2 | +++ | 1.951 | 3.20E-03 | ACTA1, ALB, P4HB, |
| T3 | +++ | 1.914 | 1.15E-03 | ACTA1, ACTC1, ALB, APOA1, |
| PPARA | + | 1.571 | 1.18E-03 | ACTA1, ALDH9A1, APOA1, PBLD, |
| PPARGC1A | + | 1.531 | 4.37E-05 | |
| SRF | --- | -1.961 | 1.49E-03 | ACTA1, ACTC1, CKM, LBD3, MYL1, |
| MAP4K4 | Inhibited | -2.000 | 6.85E-03 | |
| RICTOR | Inhibited | -3.873 | 7.58E-11 |
1 Prediction of activity of upstream regulators (positive or negative) based on activation z scores and p value of overlap (See Materials and Methods). Classification of activities are shown as predicted significantly strong positive or predicted strong negative based on a activation z score of > 2 and <−2, respectively. Qualified classifications of strong, moderate, or weak activation are indicated by +++, ++, +, respectively and qualified classification of strong inhibition is indicated by—.
2 Abbreviations: INSR, insulin receptor; IGF1R, insulin like growth receptor 1; NFE2L2, nuclear factor, erythroid 2-like 2; AMPKα, AMP activated protein kinase (α subunit), progesterone; T3, triiodothyronine; PPARA, peroxisome proliferator-activated receptor; PPARGC1A, peroxisome proliferator-activated receptor gamma coactivator 1-alpha; RICTOR, rapamycin independent companion of target of rapamycin; MAP4K4, mitogen-activated protein kinase kinase kinase kinase 4; SRF, serum response factor.
Fig 5Summary of upstream regulator analysis obtained in the proteomic dataset.
Upstream regulators predicted to be activated in breast muscle (based on expression of downstream molecules) of high FE pedigree broilers shown in orange included progesterone, triiodothyronine (T3), insulin receptor (INSR), insulin-like growth factor receptor 1 (IGF1R), peroxisome proliferator-activated receptor alpha (PPARA), peroxisome proliferator-activated receptor alpha gamma coactivator 1-alpha (PGC1α) and nuclear factor, erythroid 2-like 2 (NFE2L2). Upstream regulators predicted to be inhibited in breast muscle of the high FE phenotype shown in blue include rapamycin-insensitive companion of target of rapamycin (RICTOR), serum response factor (SRF), and mitogen-activated protein kinase 4 (MAP4K4). Orange and blue arrows indicate activation or inhibition, respectively of downstream targets. Orange lines with a bar and the end indicate the downstream target molecule would be inhibited or down-regulated in the high FE phenotype. Blue lines with a bar at the end indicate that inhibition of downstream targets would be down-regulated or diminished in the high FE phenotype. Light green arrows indicate that the expression of a downstream molecule is inconsistent with literature based results in the Ingenuity Pathway Analysis program. Proteins up-regulated in the high FE phenotype are shown in red whereas down-regulated proteins are shown in green with the complete name and fold difference in expression shown in Table 1.